Dr. Matt Hepburn Who Leads the u.s. Gov’t Covid Response on Preliminary Data Suggesting Johnson and Johnson’s Single-Dose Vaccine Is 85% Effective in Preventing Severe Cases of Covid-19.

January 29, 2021

Frankly, simple is beautiful.

  • If approved, the Johnson and Johnson (J&J) vaccine would be the first single-dose COVID-19 vaccine available. Health officials say this will streamline the vaccination process by improving access to people in rural areas and developing countries.
  • The data, based on an ongoing study with nearly 44,000 participants in the U.S. and seven other countries, suggests it is “66% effective overall in preventing moderate to severe COVID-19, 28 days after vaccination.
  • The J&J vaccine usess the same technology as the recently approved Ebola vaccine, which is different than the mRNA vaccines by Pfizer and Moderna. In some ways, it’s a more “traditional” vaccine. It uses a cold virus, modified so it cannot cause illness, to encourage the body to make harmless copies of a protein that fortifies the immune system to prepare it for if and when SARS-CoV-2 (the virus that causes COVID-19) enters.
  • *UPDATE* On February 4, J&J file an application for emergency use authorization in the U.S., with the hope of providing 100 million doses in the U.S. by June and a billion worldwide by the end of the year.
  • Why it matters: The single-dose vaccine offers hope in speeding up the vaccination process, especially in locations that lack the infrastructure to coordinate two doses for each person.

‘Simple is beautiful’: One-shot vaccine proves effective

by Jenna Lee,